Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1986 1
1989 1
1990 1
1991 2
1992 3
1993 6
1994 2
1995 2
1996 1
1997 1
1998 1
1999 2
2000 2
2001 1
2003 1
2004 1
2006 3
2007 2
2008 3
2009 3
2010 5
2011 7
2012 5
2013 13
2014 22
2015 17
2016 20
2017 18
2018 25
2019 29
2020 38
2021 36
2022 30
2023 35
2024 41
2025 35
2026 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

381 results

Results by year

Filters applied: . Clear all
Page 1
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group. Furie R, et al. Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613. Arthritis Rheum. 2011. PMID: 22127708 Free PMC article. Clinical Trial.
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Lancet. 2018 Nov 10;392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8. Lancet. 2018. PMID: 30496104 Free PMC article.
Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection.
Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, Derakhshan MH. Zamani M, et al. Aliment Pharmacol Ther. 2018 Apr;47(7):868-876. doi: 10.1111/apt.14561. Epub 2018 Feb 12. Aliment Pharmacol Ther. 2018. PMID: 29430669 Free article.
The overall prevalence of H. pylori was estimated using both random effect and fixed effect meta-analyses, and presented as prevalence rate (% and 95% CI). ...Further studies are suggested to investigate the natural history of the acquisition of H. pylori infection …
The overall prevalence of H. pylori was estimated using both random effect and fixed effect meta-analyses, and presented as prevalenc …
Endovascular thrombectomy for patients with large-core ischaemic stroke presenting up to 24 h after onset (ATLAS): a systematic review and individual patient data meta-analysis with central imaging adjudication.
Sarraj A, Thomalla G, Yoshimura S, Huo X, Costalat V, Zaidat OO, Arquizan C, Johns H, Yogendrakumar V, Churilov L, Pujara D, Sitton CW, Liebeskind DS, Inoue M, Majoie C, Beenen L, Abdulrazzak MA, Chaturvedi A, Singh S, Parsons MW, Denis A, Sakai N, Nguyen TN, Albucher JF, Kasab SA, Hassan AE, Abraham M, Rai A, Henon H, Sun D, Yamagami H, Subtil F, Bonekamp S, Uchida K, Yuan G, Gory B, Smith W, Ortega-Gutierrez S, Blackburn S, Sheth SA, Marnat G, Liu L, Shirakawa M, Fiehler J, Jensen M, Shindo S, Nogueira RG, Grandhi R, Jabbour P, Hussain MS, Dippel D, Wang Y, Yazawa Y, Simonsen CZ, Wang Y, Chen M, Hill MD, Grotta JC, Lapergue B, Jovin TG, Yoo AJ, Bendszus M, Campbell BCV, Morimoto T, Miao Z; ATLAS Investigators. Sarraj A, et al. Lancet. 2026 May 23;407(10543):2015-2026. doi: 10.1016/S0140-6736(26)00876-7. Epub 2026 May 7. Lancet. 2026. PMID: 42107392
Safety outcomes were all-cause mortality within 90-day follow-up and neurological worsening within 24-48 h of randomisation, reported as adjusted pooled relative risk (aRR); and symptomatic intracerebral haemorrhage within 36 h of randomisation (reported as risk dif …
Safety outcomes were all-cause mortality within 90-day follow-up and neurological worsening within 24-48 h of randomisation, reported …
Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
GBD 2023 Disease and Injury and Risk Factor Collaborators. GBD 2023 Disease and Injury and Risk Factor Collaborators. Lancet. 2025 Oct 18;406(10513):1873-1922. doi: 10.1016/S0140-6736(25)01637-X. Epub 2025 Oct 12. Lancet. 2025. PMID: 41092926 Free PMC article.
381 results